Literature DB >> 27907966

Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome.

Alexis A Lizarraga1, Karlo J Lizarraga1, Michael Benatar1.   

Abstract

After prompt diagnosis, severe myasthenia gravis and Guillain-Barré syndrome (GBS) usually require management in the intensive care unit. In the myasthenic patient, recognition of precipitating factors is paramount, and frequent monitoring of bulbar, upper airway, and/or respiratory muscle strength is needed to identify impending myasthenic crisis. Noninvasive ventilation can be attempted prior to intubation and mechanical ventilation in the setting of respiratory failure. Cholinesterase inhibitors should be discontinued, but resumed prior to extubation, and steroid dosage could be increased once the airway is secured. In GBS, hemodynamic and respiratory monitoring are essential; however, respiratory failure can develop rapidly and intubation with mechanical ventilation is often required and can be prolonged. Guillain-Barré syndrome can also be complicated by dysautonomia necessitating specific therapies. Prompt recognition and initiation of immunotherapy including intravenous immunoglobulin or plasmapheresis, together with supportive care including treatment of underlying infections and physical therapy, can improve outcomes in both myasthenic crisis and GBS. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27907966     DOI: 10.1055/s-0036-1592106

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  6 in total

1.  Non-invasive mechanical ventilation in myasthenic crisis outside intensive care unit setting: a safe step? Response.

Authors:  Giuliana Galassi; Alessandra Ariatti; Alessandro Marchioni
Journal:  Neuromuscul Disord       Date:  2022-03-19       Impact factor: 3.538

Review 2.  Diagnosis and Treatment of Lower Motor Neuron Disease in Australian Dogs and Cats.

Authors:  A M Herndon; A T Thompson; C Mack
Journal:  J Vet Med       Date:  2018-08-06

Review 3.  Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay.

Authors:  Giuliana Galassi; Alessandro Marchioni
Journal:  Acta Neurol Belg       Date:  2021-04-02       Impact factor: 2.396

4.  Our Clinical Experience in the Treatment of Myasthenia Gravis Acute Exacerbations with a Novel Nanomembrane-Based Therapeutic Plasma Exchange Technology.

Authors:  Dimitar Tonev; Radostina Georgieva; Evgeniy Vavrek
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

5.  Comment on "Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic status and survival" by Jakubíková et al.

Authors:  Giuliana Galassi; Alessandro Marchioni
Journal:  Eur J Neurol       Date:  2021-10-12       Impact factor: 6.089

Review 6.  Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies.

Authors:  Mario B Prado; Karen Joy Adiao
Journal:  Neurocrit Care       Date:  2021-07-22       Impact factor: 3.210

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.